Chronic Rhinosinusitis (CRS) is one of the most common chronic conditions worldwide, with a significant health-economic impact.  CRS is generally subclassified into two dominant subgroups:

• CRS with Nasal Polyps (CRSwNP), and
• RS sine (without) NP (CRSsNP).

CRS with Nasal Polyps (CRSwNP) is a Type 2 (T2) inflammatory disorder and has a significant impact on quality of life which is further reduced if other atopic diseases and asthma are also present. Whilst intranasal corticosteroids (INCS) and saline irrigation are safe and effective for long term use in patients, many patients with CRSwNP remain suboptimally controlled and require surgical management.  As new medical therapies are becoming available, a rational approach to appropriate, equitable, and cost-effective treatment is required.

A Position Paper has been developed to provide an overview of CRSwNP and provide a framework for management that includes newer biological therapies. It is available at www.allergy.org.au/hp/papers/crswnp 

This Position Paper was developed by the Australasian Society of Clinical Immunolgy and Allergy (ASCIA) and the Australian Society of Otolaryngology Head & Neck Surgery (ASOHNS) Working Party, comprising: A/Prof Raewyn Campbell, Prof Richard Harvey, Prof Connie Katelaris AM (Chair), Prof Michaela Lucas, Dr Kathryn Patchett, A/Prof Janet Rimmer and Prof Ray Sacks.

This news item was issued on 26 November 2021 by the Australasian Society of Clinical Immunology and Allergy (ASCIA), the peak professional body for clinical immunology and allergy in Australia and New Zealand.